Indegene

Princeton, United States Founded: 1998 • Age: 28 yrs Listed
Suite solutions are provided for payers and healthcare providers.
Request Access
Report Incorrect Data
Page last updated

About Indegene

Indegene is a publicly listed company based in Princeton (United States) founded in 1998 by Gaurav Kapoor, Rajesh Bhaskaran Nair, Manish Gupta, Anand Kiran, and Sanjay Suresh Parikh. Suite solutions are provided for payers and healthcare providers. Indegene has raised $220 million across 5 funding rounds from investors including The Carlyle Group, Syneos Health and Nadathur. The company has 5,666 employees. Indegene has completed 11 acquisitions, including BioPharm Communications, CultHealth and Encima Group. Indegene was last valued at $598.56 million in April 2021. Its chief executive, as recorded, is Manish Gupta. Its website indegene.com draws about 144 thousand monthly visits. Its Indian entity Indegene Limited reported revenue of ₹3,582 Cr. Its focus areas include Biopharma Outsourcing, Consulting and Diversified. Its competitors include IntegriChain and ClearView Healthcare Partners; 1 of its 2 listed competitors has raised funding.

Company details

Indegene was founded in 1998 and is headquartered in Princeton, United States. Operations focus on the healthcare sector, where suite solutions are delivered to payers and providers. Payer offerings include transformation, care management, member acquisition and engagement, healthcare analytics, and Medicare analysis. ACO solutions encompass transformation services, outcomes improvement, patient engagement, and analytics. Cloud-based platforms are operated for customer engagement, member loyalty and retention, and care management.

Recognitions & Rankings of Indegene

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#382
Valuation
₹14,190 Cr
  • Headquarters Princeton, United States
  • Employees 5,666
  • Founders Gaurav Kapoor, Rajesh Bhaskaran Nair, Manish Gupta, Anand Kiran, Sanjay Suresh Parikh
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website indegene.com
  • Social LinkedIn X Facebook
  • Legal Name Indegene Limited
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹14,781 Cr

    INDGN · NSE

  • Share Price
    ₹609.75

    -0.59% today

  • Revenue
    ₹3,510 Cr

    FY 2025-26 · +23.6% YoY

  • EBITDA
    ₹599 Cr

    Margin 17.1%

  • Net Profit
    ₹415 Cr

    FY 2025-26 · -0.5% YoY

  • P/E (TTM)
    34.9x

    P/B 4.4x

  • ROE
    13.9%

    ROCE 17.1%

  • Debt / Equity
    0.04

    Interest cover 4.1x

  • Total Equity Funding
    $220M (USD)

    in 5 rounds

  • Latest Funding Round
    $35.15M (USD), Unspecified

    Apr 2021

  • Investors
    The Carlyle Group

    & 5 more

  • Employee Count
    5,666
  • Investments & Acquisitions
    BioPharm Communications

    & 10 more

Funding Insights of Indegene

Indegene has successfully raised a total of $220M across 5 strategic funding rounds. The most recent funding activity was a Unspecified round of $35.15 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $220M
  • Total Rounds 5
  • Last Round Unspecified — $35.15M
  • Investors Count 6

All 5 funding rounds of Indegene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2021$35.15MUnspecified$598.56MCa Dawn Investment Company
Nadathur, Brighton Park Capital
Feb 2021$200MPrivate Equity Round––
The Carlyle Group, Brighton Park Capital
Jan 2020$20MPrivate Equity Round–Syneos Health
–
Jan 2005Seed––
Nadathur
Jun 2002Private Equity Round––
Karnataka Information Technology Venture Capital Fund
Valuation history
DateValuationStage
Apr 2021$598.56M••••••••

Last known valuation $598.56M (Apr 2021). 6 investors in total: 6 institutional.

Investors in Indegene

Indegene has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include The Carlyle Group, Syneos Health and Nadathur.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
The Carlyle Group
Private equity investments are directed toward multiple sectors.
1986carlyle.com
Brighton Park Capital
Brighton Park Capital is focused on growth equity investments.
bpc.comGreenwich, United States
Nadathur
Investments and philanthropy services offered by Nadathur Group.
2000nadathur.comBengaluru, India
Syneos Health
CRO clinical development services are provided by Syneos Health.
1984syneoshealth.comRaleigh, United States
Karnataka Information Technology Venture Capital Fund
India focused VC fund
1999kitven.comBengaluru, India
Ca Dawn Investment Company
Premium access

Investor details for Indegene

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Indegene Limited (Indegene)

Indegene Limited is the primary company behind Indegene. The board of Indegene Limited currently have 11 directors; the longest-serving is Rajesh Bhaskaran Nair, appointed in 1998. 13 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Rajesh Bhaskaran Nair
DIN 00219269
Director16 Oct 199828 yrsIndegene Limited
Manish Gupta
DIN 00219273
Whole-time director11 Feb 200026 yrs 8 moIndegene Limited
Sanjay Suresh Parikh
DIN 00219278
Director29 Jan 200224 yrs 9 moIndegene Limited
Krishnamurthy Venugopala Tenneti
DIN 01338477
Director22 Jul 200818 yrs 3 moIndegene Limited
Mark Dzialga
DIN 00955485
Nominee Director16 Apr 20215 yrs 6 moIndegene Limited
Ashish Gupta
DIN 00521511
Director28 Apr 20224 yrs 6 moIndegene Limited
Jairaj Manohar Purandare
DIN 00159886
Director28 Apr 20224 yrs 6 moIndegene Limited
Pravin Udhyavara Bhadya Rao
DIN 06782450
Director08 Jun 20224 yrs 5 moIndegene Limited
Georgia Nikolakopoulou Papathomas
DIN 09734940
Director30 Sep 20224 yrs 1 moIndegene Limited
Jill Mary De Simone
DIN 11483134
Director22 Jan 20269 moIndegene Limited
Neeraj Bharadwaj
DIN 01314963
Director23 Jan 20269 moIndegene Limited

People of Indegene

848 people are tracked at Indegene (147 in leadership, 6 in board & advisors, 695 in team); the tracked headcount is 5,666.

NameRoleGroup
Gaurav Kapoor
Co-FounderLeadership
Rajesh Bhaskaran Nair
Co-FounderLeadership
Manish Gupta
Co-Founder & CEOLeadership
Anand Kiran
Co-FounderLeadership
Sanjay Suresh Parikh
Co-FounderLeadership
Sanjay Parikh
Co-Founder and Executive Vice PresidentLeadership
Anuj Shah
Associate Vice President - Enterprise Business SolutionsLeadership
Tarun Mathur
Chief Technology OfficerLeadership
Samantha Olson
VP Leader Of Accounts Co CommercializationLeadership
Varun Bhargava
Director EMSLeadership
Larry Keary
Senior DirectorLeadership
Uday Ghorpade
Chief Product Officer - Data, Analytics, AILeadership
Dr.sonica Sachdeva Batra
Associate Vice President, Enterprise MedicalLeadership
Mohit Jain
Associate Vice President EuropeLeadership
Ronél Brealey
Director Learning SolutionsLeadership
Nellai Srinivasan
Director Advanced AnalyticsLeadership
Rudra Shakar Reddy Kannemadugu
Senior Director Data ManagementLeadership
Abhinav Gupta
Senior Director - Strategic SolutionsLeadership
Ravit Ansal
Chief Solutions OfficerLeadership
Dr. Vishal Shah
Vice President Leadership Organisation DevelopmentLeadership

828 more people are available in the full profile.

Premium access

Complete people profiles for Indegene

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Indegene

Indegene is a publicly listed company on the NSE with ticker symbol INDGN in India, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date13 May 2024
  • Listed onNSE: INDGN · BSE: 544172
  • Listed entityIndegene Limited
  • Exchange sectorCommercial services
  • ISININE065X01017
  • Share price₹596.90 (+2.79% on the day) · 2026-10-14
  • Market capitalisation₹13,994 Cr
  • Price to earnings36.0
  • EPS (diluted, trailing year)₹16.60
  • Dividend yield0.39%
  • Volume (last session)289,439

Financials of Indegene

Exchange-reported figures of Indegene Limited, the listed company behind Indegene (NSE: INDGN).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹3,510 Cr
+23.6% YoY
EBITDA
₹599 Cr
+12.1% YoY
Profit After Tax
₹415 Cr
-0.5% YoY
Net Worth
₹3,139 Cr
+20.0% YoY
Total Assets
₹3,574 Cr
+28.1% YoY
Total Debt
₹144 Cr
+42.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,5102,8392,5902,3061,665966643
Revenue growth+23.6%+9.6%+12.3%+38.5%+72.3%+50.3%-
EBITDA59953441439624016037.88
EBITDA margin+17.1%+18.8%+16.0%+17.2%+14.4%+16.6%+5.9%
Profit before tax52553945936322619513.68
Net profit415416335266192147(66.21)
Net profit margin+11.8%+14.7%+12.9%+11.5%+11.5%+15.2%-10.3%
EPS (₹)16.6816.9815.1712.01938.81954.66(40.25)
Balance sheet
Total assets3,5742,7912,0261,738935417476
Net worth3,1392,6161,4291,064764325211
Total debt14410249050265.7551.38168
Cash & bank38237519185.80517140180
Net working capital472705474369592280294
Cash flow
Cash from operations65144250813029717222.27
Cash from investing(508)(677)(326)(896)(158)(81.03)(15.78)
Cash from financing(82.60)288(66.20)333233(132)136
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,1221,0631,003942804761756720
Revenue growth (YoY)+39.6%+39.7%+32.8%+30.8%+17.1%+12.5%--
Other income15.0029.0010.8019.4019.7022.1025.6037.70
EBITDA186174143160141155148132
EBITDA margin+16.5%+16.4%+14.3%+16.9%+17.5%+20.4%+19.5%+18.3%
Depreciation46.4044.1041.8039.6023.4021.6020.7020.00
Interest6.906.407.204.603.803.703.103.20
Profit before tax147153105135133152149146
Tax35.1036.5025.4031.8031.0035.7031.7036.60
Net profit11211679.70103102116118110
EPS (₹)4.644.813.304.264.234.824.884.55
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,2211,0941,0461,006837511334
Revenue growth+11.6%+4.6%+4.0%+20.2%+63.7%+52.8%-
EBITDA24818016817816911742.20
EBITDA margin+20.3%+16.5%+16.1%+17.7%+20.2%+22.9%+12.6%
Profit before tax28123818117717015945.50
Net profit21217712513013313060.61
Net profit margin+17.4%+16.2%+11.9%+13.0%+15.9%+25.4%+18.1%
EPS (₹)8.817.576.215.88663.50882.67211.33
Balance sheet
Total assets2,2301,9741,035881720290368
Net worth2,0801,888954795650254312
Total debt69.8027.2038.0051.1043.8023.0046.90
Cash & bank13016415.6054.0038.8018.2036.00
Net working capital32153932737828513555.60
Cash flow
Cash from operations34612917681.9038.2053.3089.60
Cash from investing(270)(824)(189)(51.00)(267)(34.10)(51.10)
Cash from financing(62.60)717(15.80)(16.90)245(37.10)(18.50)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue368341368290307256267287
Revenue growth (YoY)+20.2%+33.3%+38.1%+1.2%+8.9%-1.2%--
Other income23.0033.906.1022.6017.5032.1035.2022.30
Total expenses297280265252236219227235
EBITDA71.8060.2010337.7070.6036.7039.6051.90
EBITDA margin+19.5%+17.7%+28.0%+13.0%+23.0%+14.4%+14.8%+18.1%
Depreciation13.1011.4010.909.508.607.306.906.50
Interest3.402.703.101.802.001.701.501.60
Profit before tax78.3080.0095.2049.0077.5059.8066.4066.10
Tax20.1020.1023.1014.2017.6014.7012.2016.20

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 07 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,1221,0631,003942804761756720
Revenue growth (YoY)+39.6%+39.7%+32.8%+30.8%+17.1%+12.5%--
Other income15.0029.0010.8019.4019.7022.1025.6037.70
EBITDA186174143160141155148132
EBITDA margin+16.5%+16.4%+14.3%+16.9%+17.5%+20.4%+19.5%+18.3%
Depreciation46.4044.1041.8039.6023.4021.6020.7020.00
Interest6.906.407.204.603.803.703.103.20
Profit before tax147153105135133152149146
Tax35.1036.5025.4031.8031.0035.7031.7036.60
Net profit11211679.70103102116118110
EPS (₹)4.644.813.304.264.234.824.884.55
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,5102,8392,5902,3061,665966643
Revenue growth+23.6%+9.6%+12.3%+38.5%+72.3%+50.3%-
Other income72.0010717058.0025.8967.263.98
Total expenses2,9122,3052,1751,9101,425806605
Employee cost2,1981,8151,6521,4651,014536370
EBITDA59953441439624016037.88
EBITDA margin+17.1%+18.8%+16.0%+17.2%+14.4%+16.6%+5.9%
Depreciation12680.2076.1059.8033.4525.5519.34
Interest19.3022.0049.4031.305.966.968.84
Profit before tax52553945936322619513.68
Tax12413312296.9063.6845.7826.12
Net profit415416335266192147(66.21)
Net profit margin+11.8%+14.7%+12.9%+11.5%+11.5%+15.2%-10.3%
EPS (₹)16.6816.9815.1712.01938.81954.66(40.25)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital48.1047.9044.4044.300.350.31316
Reserves & surplus3,0902,5671,3851,020764324(105)
Shareholders' funds (net worth)3,1392,6161,4291,064764325211
Minority interest0.000.000.000.000.008.5889.08
Secured loans0.000.0039339425.5324.76136
Unsecured loans14410296.2010840.2226.6231.71
Total debt14410249050265.7551.38168
Total liabilities3,5742,7912,0261,738935417476
Assets
Gross block2,3541,096995863271191259
Net block1,81267864666413885.91119
Capital work in progress11.803.600.000.000.000.000.00
Investments1,1001,2907966141200.0013.16
Inventories0.000.000.000.000.000.000.00
Sundry debtors982751648642444285224
Cash & bank balances38237519185.80517140180
Loans & advances15511415510748.9534.0013.64
Total current assets1,5191,2409948351,010459418
Total current liabilities1,047535520466419179124
Net working capital472705474369592280294
Total assets3,5742,7912,0261,738935417476
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash24118973.6050613317431.01
Net cash from operating activities65144250813029717222.27
Net cash from investing activities(508)(677)(326)(896)(158)(81.03)(15.78)
Net cash from financing activities(82.60)288(66.20)333233(132)136
Net change in cash59.8052.40115(433)373(40.50)143
Closing cash38237519185.80517140180
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+23.6%+9.6%+12.3%+38.5%+72.3%+50.3%-
EBITDA growth+12.1%+29.0%+4.6%+65.0%+49.6%+323.5%-
PBT growth-2.7%+17.6%+26.3%+60.3%+16.1%+1326.8%-46.8%
Net income growth-0.5%+24.3%+25.9%+38.6%+30.5%+322.2%-
Revenue CAGR (3Y)+15.0%+19.5%+38.9%+53.1%+44.4%--
EBITDA CAGR (3Y)+14.8%+30.6%+37.2%+118.7%+78.8%--
Profitability & leverage
Net income margin+11.4%+14.3%+13.0%+11.5%+9.8%+15.5%-1.9%
Return on capital employed+17.1%+23.3%+27.0%+29.5%+41.6%+59.2%0.0%
Return on net worth+13.9%+20.1%+27.0%+29.1%+34.9%+133.9%0.0%
Debt / equity0.040.150.400.310.110.410.65
Long-term debt / equity0.030.120.350.290.070.140.14
Interest cover4.094.8414.619.312.895.1647.68
Efficiency & per share
Fixed asset turnover2.042.722.794.067.204.292.84
Inventory turnover0.000.000.000.000.000.000.00
Debtors turnover4.054.064.014.254.563.804.10
EPS (₹)16.6816.9815.1712.01938.81954.66(40.25)
Dividend per share (₹)2.252.000.000.000.000.000.00
Book value per share (₹)130.49109.1764.3748.034,352.712,073.47(668.89)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue368341368290307256267287
Revenue growth (YoY)+20.2%+33.3%+38.1%+1.2%+8.9%-1.2%--
Other income23.0033.906.1022.6017.5032.1035.2022.30
Total expenses297280265252236219227235
EBITDA71.8060.2010337.7070.6036.7039.6051.90
EBITDA margin+19.5%+17.7%+28.0%+13.0%+23.0%+14.4%+14.8%+18.1%
Depreciation13.1011.4010.909.508.607.306.906.50
Interest3.402.703.101.802.001.701.501.60
Profit before tax78.3080.0095.2049.0077.5059.8066.4066.10
Tax20.1020.1023.1014.2017.6014.7012.2016.20
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,2211,0941,0461,006837511334
Revenue growth+11.6%+4.6%+4.0%+20.2%+63.7%+52.8%-
Other income78.3090.4050.3036.8027.8063.6020.10
Total expenses972913878828668394292
Employee cost795759752701526273187
EBITDA24818016817816911742.20
EBITDA margin+20.3%+16.5%+16.1%+17.7%+20.2%+22.9%+12.6%
Depreciation36.3026.2031.1031.7023.6017.6013.40
Interest8.706.206.606.403.003.503.40
Profit before tax28123818117717015945.50
Tax69.5057.2042.7046.4037.2026.9013.80
Net profit21217712513013313060.61
Net profit margin+17.4%+16.2%+11.9%+13.0%+15.9%+25.4%+18.1%
EPS (₹)8.817.576.215.88663.50882.67211.33
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital48.1047.9044.4044.300.400.30316
Reserves & surplus2,0321,839909751650254(3.40)
Shareholders' funds (net worth)2,0801,888954795650254312
Secured loans0.000.000.000.000.000.0021.40
Unsecured loans69.8027.2038.0051.1043.8023.0025.50
Total debt69.8027.2038.0051.1043.8023.0046.90
Total liabilities2,2301,9741,035881720290368
Assets
Gross block25318317518714999.4072.50
Net block11352.8056.1078.3072.0040.6031.30
Capital work in progress11.803.600.000.000.000.000.00
Investments1,31897562440020383.40251
Inventories0.000.000.000.000.000.000.00
Sundry debtors28841837840135017559.70
Cash & bank balances13016415.6054.0038.8018.2036.00
Loans & advances15513311979.3026.3024.6022.80
Total current assets573715513534415218118
Total current liabilities25217618515613082.5062.90
Net working capital32153932737828513555.60
Total assets2,2301,9741,035881720290368
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash35.2013.2041.8027.8011.6029.509.50
Net cash from operating activities34612917681.9038.2053.3089.60
Net cash from investing activities(270)(824)(189)(51.00)(267)(34.10)(51.10)
Net cash from financing activities(62.60)717(15.80)(16.90)245(37.10)(18.50)
Net change in cash13.3022.00(28.60)14.0016.20(17.90)20.00
Closing cash13016415.6054.0038.8018.2036.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+11.6%+4.6%+4.0%+20.2%+63.7%+52.8%-
EBITDA growth+37.5%+7.4%-5.6%+5.5%+44.4%+176.8%-
PBT growth+18.0%+32.1%+2.3%+3.9%+6.7%+250.1%-23.0%
Net income growth+19.9%+41.9%-4.4%-1.9%+2.1%+114.4%-
Revenue CAGR (3Y)+6.7%+9.3%+27.0%+44.3%+43.7%--
EBITDA CAGR (3Y)+11.7%+2.3%+12.9%+61.5%+47.5%--
Profitability & leverage
Net income margin+17.4%+16.6%+13.2%+13.0%+15.9%+25.9%+9.5%
Return on capital employed+13.8%+16.3%+19.5%+22.9%+34.2%+47.7%+26.3%
Return on net worth+10.7%+12.8%+15.8%+18.0%+29.4%+96.4%+67.5%
Debt / equity0.020.020.050.070.070.120.14
Long-term debt / equity0.020.010.040.050.050.050.03
Interest cover4.114.024.824.382.073.5311.81
Efficiency & per share
Fixed asset turnover5.606.105.775.976.735.956.17
Inventory turnover0.000.000.000.000.000.000.00
Debtors turnover3.452.752.692.683.194.356.09
EPS (₹)8.817.576.215.88663.50882.67211.33
Dividend per share (₹)2.252.000.000.000.000.000.00
Book value per share (₹)86.4978.8042.9635.913,250.001,692.67(20.67)

Investments & Acquisitions by Indegene

Indegene has strategically engaged in corporate development activities, having acquired 11 companies. Notable acquisitions include BioPharm Communications, CultHealth and Encima Group.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
BioPharm Communications
Marketing services are provided to pharmaceutical and biopharma companies.
biopharmcommunications.comNew Hope, United States2005Oct 2025••••
MJL
Brand strategy services are delivered from Hitchin, United Kingdom.
mjl.co.ukHitchin, United Kingdom1981Mar 2025••••
Trilogy Writing & Consulting
Medical writing services are provided to healthcare clients.
trilogywriting.comFrankfurt Am Main, Germany2002Mar 2024••••
CultHealth
Health care marketing services are provided to clients by CultHealth.
culthealth.comNew York, United States2005Oct 2022••••
MME
Marketing services to the pharmaceutical industry are provided.
mmeadvisors.comOxford, United States2002Aug 2021$10M
Wincere
A clinical data management and clinical and statistical programming solutions
wincere.comSanta Clara, United States2005Dec 2016••••
Encima Group
Omni-channel analytics solutions are provided for pharma marketing teams.
encimagroup.comNewark, United States2006Dec 2016$16M
Skura Corporation
Mobile sales enablement solutions are provided to life sciences firms.
skura.comOakville, Canada1996Apr 2016$9M
Vantage Point HIS
Healthcare analytics for risk analysis and resource utilization are provided.
vantagepointinc.comDanbury, United States1989Dec 2015••••
TTM Colombia
Limited information available
ttm.com.coColombia2010Jan 2014••••
Premium access

Complete acquisition details for Indegene

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Indegene

15 dated milestones of Indegene across 27 years, from founding to its latest funding, stage changes and deals.

  1. Founded Indegene is founded.
  2. Funding First funding round.
  3. Acquisition Acquires TTM Colombia.
  4. Acquisition Acquires Vantage Point HIS.
  5. Acquisition Acquires Skura Corporation.
  6. Acquisition Acquires Encima Group.
  7. Acquisition Acquires Wincere.
  8. Funding Latest funding round, Unspecified, of $35.2M.
  9. Milestone Reaches Minicorn status.
  10. Acquisition Acquires MME.
  11. Acquisition Acquires CultHealth.
  12. Acquisition Acquires Trilogy Writing & Consulting.
  13. IPO Lists on the stock exchange (IPO).
  14. Acquisition Acquires MJL.
  15. Acquisition Acquires BioPharm Communications.

Competitors of Indegene

Indegene has 2 listed competitors in our database, 1 of them funded. They include IntegriChain and ClearView Healthcare Partners.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
IntegriChain
integrichain.com2005Philadelphia, United States$2M320
Inventory, order and customer relationship management solution for life science suppliers.
ClearView Healthcare Partners
clearviewhcp.com2008Newton, United States381
Strategic consulting services are provided to life sciences companies.
Premium access

Detailed competitors of Indegene

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Indegene

The website of Indegene (indegene.com) receives about 143.6K visits a month.

  • Monthly visits
    143.6K

    ▲ 115.4% vs previous month

Similar websites

Websites whose visitors overlap most with Indegene. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Indmedica
indmedica.com
100%
#2,411,861View details
MedCLIK
medclik.com
91%
View details
Apollo Life
apollolife.com
86%
View details
Isabel Healthcare
isabelhealthcare.com
82%
#577,341View details
Vaatsalya
vaatsalya.com
82%
View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 24 similar websites and full traffic analytics for Indegene

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 24 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Indegene (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Insulet
Wearable insulin infusion systems are developed for diabetes patients.
2000Boston, Massachusetts, United StatesUSD 120.4 MUSD 2.71 B3,900
MannKind Corp
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Pfizer
Pharmaceutical products for treating multiple diseases are provided.
1849New York, New York, United StatesUSD 8 MUSD 266.99 M1,770
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Indegene

INDGN: Q2 REVENUE 11.22B RUPEES VS 8.04B (YOY)
Exchange Update • 9 days ago
INDGN: Q2 CONS NET PROFIT 1.12B RUPEES VS 1.02B (YOY)
Exchange Update • 9 days ago
INDGN: Q2 EBITDA 1.86B RUPEES VS 1.41B (YOY); Q2 EBITDA MARGIN 16.55% VS 17.48% (YOY)
Exchange Update • 9 days ago
Indegene: Company Creates Step-Down Fully Owned Subsidiary Indegene Portugal.
Exchange Update • 12 days ago
Indegene: Company Plans to Review Q2 Financial Results on October 29.
Exchange Update • 1 month ago
Indegene shares rise 5% as Motilal Oswal upgrades stock; check target price - BusinessToday
Business Today • 1 month ago
Buy Indegene; target of Rs 708: Motilal Oswal
Moneycontrol • 1 month ago
Indegene shares rise as Motilal Oswal upgrades stock, sets target at ₹708 - CNBC TV18
CNBCTV18 • 1 month ago
Indegene Says U.S. Court Preliminarily Approves Proposed Class Action Settlement On Aug 27, 2026
Reuters • 2 months ago
Indegene US arm gets preliminary court approval for $4.72-million class-action settlement - CNBC TV18
CNBCTV18 • 2 months ago
Premium access

Complete news archive for Indegene

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Indegene

Indegene was founded in 1998 and raised its 1st funding round 4 years after it was founded.

Indegene is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.

Manish Gupta is the CEO of Indegene, as recorded in our data. They have also founded this company.

Indegene is a funded company, having raised a total of $220M across 5 funding rounds to date.

Indegene has 5,666 employees.

The primary company behind Indegene, Indegene Limited, reported revenue of ₹3,582 Cr for FY 2026, up 24% year on year.

Indegene was founded in 1998 and is headquartered in Princeton, United States. Operations focus on the healthcare sector, where suite solutions are delivered to payers and providers. Payer offerings include transformation, care management, member acquisition and engagement, healthcare analytics, and Medicare analysis. ACO solutions encompass transformation services, outcomes improvement, patient engagement, and analytics. Cloud-based platforms are operated for customer engagement, member loyalty and retention, and care management.

Indegene's top competitors include IntegriChain and ClearView Healthcare Partners.

Yes, Indegene is publicly traded on NSE under the ticker symbol INDGN.

Indegene has made 11 acquisitions, including BioPharm Communications, CultHealth, and Encima Group.

Indegene has 6 investors. Key investors include The Carlyle Group, Syneos Health, Nadathur, Karnataka Information Technology Venture Capital Fund, and Brighton Park Capital.

The valuation of Indegene is $598.56M as of Apr 2021.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available